<DOC>
	<DOCNO>NCT01977300</DOCNO>
	<brief_summary>Hypothesis : Continuation atypical antipsychotic medication combination Mood Stabilizer , follow remission acute manic episode , lower rate relapse recurrence mood episode compare discontinue antipsychotic within day resolution manic symptom .</brief_summary>
	<brief_title>Atypical Antipsychotics Continuation Maintenance Treatment After Acute Manic Episode</brief_title>
	<detailed_description>This randomise , double-blind , placebo control trial 52 week . Patients one four combination medication time entry study : ) lithium risperidone , b ) lithium olanzapine , c ) valproate risperidone , ) valproate olanzapine . After obtain informed consent , patient randomise one three group 1 ) '' 0 '' week group : patient receive lithium valproate plus placebo 52 week ( risperidone olanzapine taper begin day randomisation discontinuation drug within 2 week ) , 2 ) continuation atypical antipsychotic , risperidone olanzapine , plus lithium valproate 24 week ( taper antipsychotic begin end 24 week complete within 2 week ) follow mood stabilizer plus placebo another 28 week , 3 ) continuation atypical antipsychotic , risperidone olanzapine , plus lithium valproate 52 week . The duration double-blind phase study 52 week patient continue mood stabilizer , lithium valproate , acute mania full duration study . The serum level mood stabilizer maintain within therapeutic range ( 0.6 1.2 mmol/L lithium 50 125 ug/L valproate ) throughout 52 week determine blood test . The dose type atypical antipsychotic ( ie risperidone olanzapine ) patient receive double-blind period patient time entry double-blind phase . All patient , irrespective treatment arm , receive active psychoeducation counsel regard sleep hygiene , healthy daily routine rhythm , alcohol substance abuse , anxiety management , conflict resolution problem solve clinically indicate routine clinical practice . Patients withdraw meet primary end point study treat actively do regular clinical practice . Patients allow receive psychotropic medication exception benzodiazepine sedation anti-parkinsonian medication extrapyramidal side effect . The dos record .</detailed_description>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patients recently ( within last 12 week ) commence treatment Diagnostic Statistical Manual Mental Disorders ( DSMIV ) manic mixed episode combination lithium risperidone , lithium olanzapine , valproate risperidone , valproate olanzapine ; Patients 1 6 mg risperidone 5 25 mg olanzapine Patients remission mania least 2 week 6 week maintain remission 2 consecutive week ; Patients must take psychotropic medication ( exception benzodiazepine ) treatment include bromocriptine , omega 3 fatty acid , Axid EMPower ; Patients age 17 . Any subject meet inclusion criterion exclude study . In order finding generalizable clinically representative patient bipolar disorder , patient history comorbid substance abuse medical illness exclude .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>